. Author manuscript; available in PMC: 2012 Jun 1.

Published in final edited form as: Exp Parasitol. 2011 Feb 19;128(2):170–175. doi: 10.1016/j.exppara.2011.02.016

Table 1.

Comparison of in vitro potency of drugs used in this study.

Drug target	IC₅₀ of drug (nM)

	RWJ68198	RWJ67657	SD-282	SB203580	SB202474	chloroquine	mefloquine

P. f. W2	380 ± 20	2,710 ± 190	8,800 ± 260	13,240 ± 990	19,530 ± 120	424 ± 22	3.59 ± 0.46
P. f. HB3	860 ± 60	7,630 ± 350	9,780 ± 790	12,610 ± 570	24,560 ± 330	22.0 ± 2	11.2 ± 0.90
human p38α^a	22	1,000	1.6	7,000	> 10	N/A^d	N/A^d
T. g. TgMAPK-1^b	ND^c	200	ND^c	135	> 10	N/A^d	N/A^d

IC₅₀ data are derived as the mean and standard deviation of 3 independently derived IC₅₀ values.

The reported IC₅₀ value for the inhibition of purified recombinant human p38α kinase activity are taken from the following sources: RWJ68198, (Dodd et al., 2000, Rupert et al., 2003); RWJ67657, (Wadsworth et al., 1999); SB202474, (Halawani et al., 2004); SB203580, (Brumlik et al., 2004, Wadsworth et al., 1999), and SD-282 (Sweitzer et al., 2004).

The reported IC₅₀ value for the inhibition of TgMAPK-1 autophosphorylation is taken from the following sources: SB203580, (Brumlik et al., 2004); RWJ67657 or SB202474, (Brumlik et al., unpublished observations).

ND; The IC₅₀ value has not been determined.

N/A; Not applicable.